Article Details

Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy

Retrieved on: 2023-11-19 23:03:18

Tags for this article:

Click the tags to see associated articles and topics

Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy. View article details on HISWAI: https://www.pharmiweb.com/press-release/2023-11-19/bayer-aktiengesellschaft-oceanic-af-study-stopped-early-due-to-lack-of-efficacy

Excerpt

... atrial fibrillation at risk for stroke is being stopped early. This decision is based on the recommendation of the study's Independent Data ...

Article found on: www.pharmiweb.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up